The prevalence of epilepsy is generally taken as between 5 and 10 cases per 1000 persons, and the overall incidence as about 50 cases per 100 000 persons. The rates are dependent on case ascertainment and on definitions used. The prognosis depends on many factors, including the number of seizures at presentation, the seizure type and the use of anti-epileptic drugs. Epilepsy carries an excess mortality; the cause of death can be unrelated to epilepsy, related to the underlying disease causing epilepsy, or related to epilepsy itself.
EPIDEMIOLOGY
Epidemiology is the study of the distribution and determinants of disease in human populations; the study of the dynamics of a medical condition in the community. It can be divided into three aspects: descriptive, analytical and experimental.
Descriptive epidemiology concerns the incidence and prevalence, and natural history (prognosis and mortality) of a condition. Descriptive studies may be thought of as observational, with no designed control group. Analytical epidemiology compares those with a disease or risk factor with those without, for example in cross-sectional, cohort and case control studies. Studies under conditions that allow an investigator to control relevant factors constitute experimental epidemiology. The epidemiology of epilepsy is largely based on descriptive and analytical studies.
DEFINITIONS
The incidence rate of a condition is the number of persons who become diseased during a defined period divided by the total person-time at risk during that period. It is generally expressed as the number of cases per 100 000 people in the population per year. The point prevalence is the number of diseased persons in a defined population at one point in time, divided by the number of persons in that population and time.
Despite epilepsy being amongst the most common serious neurological conditions, the reported incidence and prevalence figures vary widely. This can be due to differences in case ascertainment, differences in age groups studied, and differences in the location of the study.
Case ascertainment
Until the 1960s, studies of epilepsy were based on patients seen in tertiary referral centres 1 . These tended to show that epilepsy was a chronic, progressive and incurable disorder, as milder cases were underrepresented. Similarly, studies based on a retrospective review of medical notes for seizures, anti-epileptic drugs (AEDs) or diagnostic codings may lead to inaccuracy and under-reporting 2 . In a study of subjects with epilepsy found during a field survey in Warsaw, one third had never been treated for epilepsy, over a quarter had stopped treatment, and over a quarter had not been diagnosed as having epilepsy. Some did not suspect that their transient symptoms could be epilepsy 3 .
Incidence figures vary because of differences in inclusion criteria. If febrile seizures, neonatal seizures or single seizures are included the figures may be elevated several-fold. Similarly, acute symptomatic seizures account for up to one third of all newonset seizures, and are often not classified as epilepsy. Clearly, the inclusion criteria should be specified when epidemiological rates are quoted.
Prevalence data will vary according to whether only active epilepsy is considered, and upon the definition of 'active epilepsy'.
Age groups
The incidence of epilepsy is high in childhood, decreases in young people and rises again in the elderly 4 . About 50% of cases of epilepsy start in the two extremes of life, with half of those being under one year. Epilepsy has a high incidence in the elderly and this may be because of demographic changes in the population, with increasing numbers of people surviving into old age, with significant morbidity. The major cause of epilepsy in the elderly is cerebrovascular disease (CVD), although paradoxically the incidence of CVD has decreased over the last three decades.
Location
Epilepsy occurs throughout the world, but higher incidence figures are generally found from studies in developing countries. The reasons for this may be multiple. The incidence of epilepsy is particularly high in Latin America and in several African countries. Parasitic infections have been suggested as important aetiological factors for epilepsy in these countries, as have intracranial infections, perinatal brain damage and hereditary factors 5 . No consistent racial differences have been found, although several studies from the United States show higher incidence and prevalence figures amongst black Americans when compared with white Americans. Epilepsy is usually found to be slightly more common in the lower socioeconomic groups. Two recent studies in the UK and the USA have shown lower prevalence and incidence rates respectively in the South Asian population 6, 7 . However, there have been acknowledged sampling problems in both studies, and suggested bias includes selective migration and healthy worker effects.
THE INCIDENCE AND PREVALENCE OF EPILEPSY
The overall incidence of epilepsy, excluding febrile convulsions and single seizures, is generally taken to be about 50 cases per 100 000 persons per year (range 40 to 70 per 100 000/year) 2 in developed countries. In developing countries a range of 100 to 190 per 100 000 per year is generally quoted 2 .
The prevalence of epilepsy is usually regarded as between 5 and 10 cases per 1000 persons, excluding febrile convulsions, single seizures and inactive cases. The lifetime prevalence of seizures is between 2 and 5%. Over two-thirds of patients enter long-term remission, and subsequent relapse is uncommon.
CLASSIFICATIONS OF EPILEPSY
Epilepsy can be classified in a number of ways, and each has its uses and problems. The prognosis of epilepsy is often determined to a large extent by its aetiology, and so a classification including this is to be encouraged.
Seizure type
The seizure type is frequently classified according to the International Seizure Classification proposed by the International League against Epilepsy (ILAE), which is based on clinical and electroencephalographic (EEG) features of the seizure 8 . This scheme divides seizures into three groups: generalized, partial (or localization-related) and unclassified. Generalized seizures are those in which epileptic discharges involve both cerebral hemispheres from the onset of the seizure, whereas partial seizures are those in which the epileptic activity is confined to a focal area of the brain. Generalized seizures are subdivided into tonicclonic, absence, myoclonic, atonic, tonic and clonic seizures. Partial seizures are subdivided into simple partial seizures, where consciousness is preserved, and complex partial seizures where consciousness is impaired. Partial seizures may also become secondarily generalized if the epileptic activity spreads to involve both cerebral hemispheres.
In general, partial seizures account for most cases. The National General Practice Study of Epilepsy (NGPSE), a prospective population-based cohort of patients with newly diagnosed epileptic seizures, classified the seizure type of 564 subjects. At 6 months 11% were classified as having complex partial seizures, 3% simple partial seizures, 27% secondarily generalized seizures, 35% primarily generalized tonic-clonic seizures, and less than 1% each generalized absence and myoclonus. Fourteen percent were mixed (partial or generalized) and 9% were unclassifiable 4 .
This classification does not take into account the aetiology or any anatomical features, and rarely gives any guide to prognosis.
Aetiology
The aetiology of epilepsy is frequently multifactorial, and exact attribution of cause is often impossible. About 60% of epilepsies have no clear cause, although advances in magnetic resonance imaging (MRI) have increased the number of patients in whom a positive putative aetiological diagnosis is possible. A recent community-based MRI study found that in newly diagnosed patients, a relevant putative aetiology could be found in 70% of those with partial onset seizures and 30% of those with generalized seizures 9 . The increasing availability of high-resolution MRI should improve the ability to determine the causes of epilepsy.
Epilepsy syndrome
In 1989 the ILAE suggested a new classification, now taking into account seizure type, EEG, and prognostic, pathophysiological and aetiological data 10 . This classification also divides epilepsies into seizure type (localization-related, generalized or undetermined), but further divides them into idiopathic, symptomatic, or cryptogenic, according to the putative cause. Symptomatic epilepsy is considered to be the consequence of a known disorder of the central nervous system, cryptogenic epilepsy is presumed to be due to an underlying but unidentified focal abnormality and idiopathic epilepsy is reserved for those syndromes which are presumed to be inherited.
Unfortunately, although this is a comprehensive classification, it is too complicated to be of utility in clinical practice and epidemiological research, and takes no account of recent developments in neuroimaging and neurogenetics 11 .
PROGNOSIS OF EPILEPSY
Prognosis in epilepsy is usually taken as the prospect of attaining complete seizure freedom once a pattern of recurrent epileptic seizures has been established. Seizures are a symptom of disease, and do not constitute a single well-defined illness. As a consequence of this, the prognosis depends on many factors; aetiology, age of onset, number of seizures at onset, the natural history of the condition and the influence of treatment. However, overall between 70 and 80% of people developing epilepsy will go into long-term remission, usually within the first 5 years.
The most important consideration of prognosis in epilepsy is the likelihood of seizure freedom, with or without the use of antiepileptic drugs (AEDs). As most patients with a history of more than one seizure are generally prescribed an AED, the prognosis has been more fully investigated in this group. Generally the 1 year remission rate is between 65 and 80% 12a .
Recurrence after a first seizure
Historically, single seizures have been regarded as different from epilepsy, largely because early studies suggested that most subjects with a first seizure have no further attacks. However, as early as 1975 it was found that the incidence of epilepsy was much higher than that of single seizures, suggesting that many such patients will undergo seizure recurrence 12 . In a General Practice study in Tonbridge, UK, it was found that seizures recurred in four out of five patients after the first seizure 13 . A recent retrospective study of recurrence after a first untreated tonic-clonic seizure in Hong Kong showed that 30% experienced another seizure within the first year, and a further 17% within the next 3 years 14 . However, this study ignored all but tonic-clonic seizures, which may have affected the recurrence rate, as the risk of recurrence is higher for other seizure types 15 .
There are many problems involved in determining the rate of recurrence after a first seizure, most related to case ascertainment. Although most subjects experiencing a first tonic-clonic seizure will seek medical advice, other seizure types may not be immediately recognized as epilepsy. In a large study in Australia 17% of those presenting with tonicclonic seizures had had previous tonic-clonic seizures which were unwitnessed, not medically assessed or incorrectly diagnosed. Of 43 patients presenting with non-tonic-clonic seizures, 60% had experienced similar episodes in the past and had not sought medical advice 16 .
The risk of seizure recurrence is greater in the first weeks or months after an initial seizure. If there is a long interval between the initial seizure and recruitment into a study a second seizure may already have occurred, thus excluding the subject from the study. A large hospital-based study in London showed the recurrence at 2 years to be 51% in those recruited in under a week, but only 15% in those recruited more than 8 weeks after the first seizure 17 . Communitybased studies are perhaps more likely to pick up first seizures than those based in hospitals; in the NGPSE, when all seizure types were considered, 67% of subjects had a recurrence within 12 months of the first seizure, and 78% within 36 months, all seizure types are considered 18 .
The first seizure is also not a clinical entity in itself, and different aetiologies may have different natural histories.
Seizure type
Seizure type has been thought to be an important predictor of recurrence risk. Partial seizures have a poor prognosis for remission: in studies of American adults complex partial seizures were controlled in only 23 to 26% of patients, whereas secondarily generalized attacks were controlled in 48 to 55% at 1 year 19 . The early findings of the NGPSE also suggested that recurrence rates were much higher with partial seizures than with tonic-clonic seizures, and with remote symptomatic seizures than with acute symptomatic seizures 18 . However, later review showed no significant difference for chances of remission between primary generalized tonic-clonic seizures, partial seizures only, any partial seizures, secondarily generalized seizures or any generalized tonic-clonic seizures 20 . This study showed that the predominant clinical factor that seemed to predict prognosis was the number of seizures occurring in the first 6 months after presentation. Other factors, including seizure type, seemed to be unimportant or to be variables associated with this single important prognostic factor. The authors suggest that this may be because epilepsy in any individual patient has an inherent severity and response to treatment, and that severely affected patients are difficult to control from early in their condition. They also note that a potential confounding factor is the differential mortality for patients with severe underlying pathological findings who were followed for shorter periods because of death. The finding of the prognostic significance of the number of early seizures is in accordance with other studies showing that most patients who entered remission did so in the first 2 years, and that the prospect of entering remission decreased as time elapsed 13 .
Time of starting AEDs
Those who have had two or more unprovoked seizures are usually started on AEDs. Patients with just one unprovoked seizure are not routinely treated in the UK, perhaps in view of the fact that not all these will go on to develop epilepsy. In a hospital-based study, subjects presenting within 7 days of a first unprovoked tonic-clonic seizure were randomized to receive AEDs immediately or only in the event of seizure recurrence 21 . The overall risk of recurrence was greatest initially. Starting AED treatment after the first seizure, compared with starting treatment after seizure recurrence, reduced the risk of relapse over the first 2 years, but did not affect the long-term probability of 1 or 2 year remission.
AED usage
Several studies have looked at the prognosis with use of different AEDs. An early study showed improved seizure control with carbamazepine or phenytoin, compared with phenobarbitone or primidone 22 . In a more recent study of 525 patients with newly diagnosed epilepsy, patients were either given an appropriate AED for the type of seizures and other clinical indications, or were randomized to receive an unknown AED. There was no significant difference in the seizure-free rate between those taking established AEDs and those taking newer ones 23 . Amongst the patients who had never before received an AED, 47% became seizure-free on their first AED and a further 14% became seizure-free on a second or third drug. Additionally, 3% were controlled by a combination of two AEDs. These results suggest that the response to the first AED is a powerful prognostic factor. Furthermore, the reason for failure of the first AED is prognostically important; of those who changed drugs because of lack of efficacy, 11% became seizure-free on a subsequent drug. Where the first drug failed because of intolerable side-effects or idiosyncratic reactions, 41 and 55% respectively, became seizurefree on a second AED.
The cause of drug resistance in epilepsy is poorly understood. Early work has suggested there may be non-tumoural overexpression of a multidrugresistance protein in some cases of focal cortical dysplasia 24 . Whether this can be extended to other causes of epilepsy is unclear.
Refractory epilepsy
Community and hospital studies of newly diagnosed epilepsy have shown that 20-30% of patients do not enter remission. The prevalence of persistent seizures seems to be higher in subjects with symptomatic or cryptogenic epilepsy than in those with idiopathic epilepsy 23 .
However, between 10 and 20% of patients referred to clinics with 'refractory epilepsy' may have been misdiagnosed 2, 25 . In the latter study, of 92 patients referred to a single consultant with a diagnosis of 'refractory seizures', 13% did not have epilepsy, and a further 44% were significantly improved by the optimal use of AEDs or epilepsy surgery. The authors found that incomplete history-taking and misinterpretation of the EEG appeared to be the principal causes for misdiagnosis.
Withdrawal of AEDs
If long-term seizure control is achieved with AED use, the decision has to made whether or not to withdraw the AEDs. For each patient the risk-benefit ratio has to be considered; AEDs are not without side-effects, but employment and driving risks ensue if seizures return.
Numerous studies have been undertaken to try to establish the risk of recurrence after AED withdrawal. A meta-analysis found the risk to be about 25% at 1 year and 29% at 2 years 26 . There appeared to be an increased risk of relapse associated with adolescentonset epilepsy; childhood-onset epilepsy has the most favourable risk figure. The large Medical Research Council study compared slow withdrawal of AEDs with continuation of AEDs, and found the risk of recurrence to be substantially larger at 2 years in those randomized to slow withdrawal compared with those randomized to continuation (41% and 22% respectively) 27 . By 2 to 4 years after the start, patients still seizure free may have a higher risk of relapse when randomized to continue medication than those randomized to withdrawal. The reasons for this are not certain; patients randomized to continue medication may have withdrawn after one or two years, or those who were still seizure free taking no AEDs may have remitted, whereas those still seizure free on medication may only have been so because of their AEDs. This study found that the most important predictors of risk were longer seizure-free periods, which reduced the risk, and the use of more than one AED before remission and a history of tonicclonic seizures or myoclonic seizures, which increased the risk. Further follow-up of the subjects in this study who had a seizure recurrence showed that the prognosis is still relatively good whether or not AEDs were withdrawn 28 .
Untreated epilepsy
In the developed world, most people are started on AEDs at the time of their second seizure or earlier.
It is hard to conduct studies comparing the course of treated epilepsy with that of untreated epilepsy. A study in Holland of children with untreated newly diagnosed tonic-clonic seizures found that about 40% of these children had a decelerating pattern of seizures; that is the child became free of seizures without AEDs or the time intervals between seizures successively increased 29 . This study included only children with tonic-clonic seizures, and only those with idiopathic or remote symptomatic seizures.
In the Warsaw field study, almost one-third of those who had never been treated were free of seizures for more than 5 years 3 . Some of these had had frequent generalized seizures in the past. A small study in Finland, looking at untreated epilepsy, found the probability of remission to be 42% by 10 years after the onset of epilepsy 30 .
Epilepsy is less likely to be treated in the developing world, and may provide an estimate of the prognosis of untreated epilepsy. However, the aetiologies may be very different from those in the developed world, and this may affect the prognosis. If epilepsy rarely remits when untreated, then the prevalence rates for epilepsy would be expected to be much higher in the developing world. Although this has sometimes been found to be the case it is by no means always so. The lack of higher prevalence rate in the developing world could be explained in part by the higher mortality rate of epilepsy or the shorter life expectancy. Although case ascertainment could be different in the two areas, it is more likely that cases in remission would be missed in the developing world, rather than those with active epilepsy. A more likely explanation is that many untreated cases enter spontaneous remission.
A study in a rural area of Northern Ecuador in the early 1990s identified over 1000 people with epilepsy 31 . Only 37% of these had ever received AEDs. Despite this, over 40% were free of seizures, of whom almost two-thirds had never received AEDs. Additionally, a treatment programme was instituted amongst almost 200 people with active untreated epilepsy. The effectiveness of new treatment with AEDs was as good as that seen in new cases in developed countries.
Prognosis according to aetiology and response to treatment
It is seen that the prognosis of epilepsy is based on multiple factors including the number of seizures at presentation, seizure type and AED usage. The syndromic classification, although complicated, difficult to apply in many forms of clinical practice and nowadays somewhat out of date, nonetheless is a useful basis for grouping seizures into prognostic groups. People with seizures can be categorized into four prognostic groups 19, 32 :
(1) Excellent prognosis. This group comprises about 20-30% of all people who develop epileptic seizures. Usually only a few seizures occur and spontaneous remission is the rule. Conditions include benign idiopathic or familial neonatal convulsions 33 , the benign partial epilepsies 34 , benign myoclonic epilepsy of infancy and acute symptomatic seizures 35 .
(2) Good prognosis. This group comprises about 30-40% of people who develop epilepsy. Seizures are easily controlled with AEDs and, once remission is achieved, it is usually permanent. Conditions include childhood absence epilepsy 34 , epilepsy with generalized tonic-clonic seizures on awakening 35 , nonspecific generalized tonic-clonic seizures in patients with no abnormal neurological signs, and some of the localization-related epilepsies.
(3) AED-dependant prognosis. In this group, comprising some 10-20% of people who develop epilepsy, there is a long-term tendency to seizures. AEDs suppress seizures and patients may achieve remission, but may relapse if AEDs are stopped. Juvenile myoclonic epilepsy is well known for this behaviour 34 , which also occurs in the majority of localization-related epilepsies. Some patients with localizationrelated epilepsies may be treated by surgery, with change of prognostic group.
(4) Bad prognosis. Up to 20% of people with epilepsy may be in this group, in whom AEDs are palliative rather than suppressive of seizures. Despite intensive treatment with AEDs, seizures tend to occur. A few patients may respond to novel AEDs or to surgical treatment. Conditions with this poor prognosis include seizures associated with neurological deficit present from birth (tuberous sclerosis, Sturge-Weber syndrome, malformations, cerebral palsy, etc), epilepsia partialis continua 34 , progressive myoclonic epilepsies and other progressive neurological diseases, West syndrome 36 , Lennox-Gastaut syndrome 34 and others in which atonic/tonic seizures are a prominent feature, partial seizures associated with gross structural lesions and some of the localization-related cryptogenic epilepsies.
MORTALITY IN EPILEPSY Definition
The mortality rate for a disease is generally quoted as the standardized mortality ratio (SMR), which is defined as the observed number of deaths in the study population divided by the expected number of deaths in the study population, if the age-and sexspecific mortality rates were the same as those of the standard population. Thus the SMR measures how much more, or less, likely a person is to die in the study population compared with someone of the same age and sex in the standard population. Despite an overall good prognosis for seizure control, epilepsy is a potentially life-threatening condition and carries an excess mortality. The SMR for epilepsy is 2-3, and may be higher in males than females.
Cause of death
The cause of death in people with epilepsy can be unrelated to epilepsy, related to the underlying disease causing epilepsy, or related to epilepsy; the distinction between these is not always clear-cut in an individual case 37 . In similar ways to the other epidemiological variables, mortality rates in epilepsy can be hard to quantify, particularly in retrospective studies. Death certificates do not always mention epilepsy as the direct or underlying cause of death, and, as noted earlier, people with mild epilepsy may not have consulted the medical profession. Prospective studies based in the community are the most likely to provide an accurate estimate of SMRs, but the studies need to be large enough to be able to assess less frequent causes of death, such as certain neoplasms and suicide 38 .
A large study in Sweden of mortality in patients once hospitalized for epilepsy (4001 deaths) 38 , a smaller community based study in the UK (214 deaths) 39 and a hospital based study in the Netherlands (404 deaths) 40 together provide some statistics. Despite the large differences in case ascertainment, for many causes of death there is remarkable agreement ( Table 1) . The difference in overall SMR may be that mild cases are never hospitalized and so do not contribute to the deaths in the Swedish study.
In the NGPSE, with a median follow-up period of 11.8 years, SMRs were raised in patients with acute symptomatic epilepsy, remote symptomatic epilepsy and epilepsy due to congenital neurological deficits 39 . This increase was most prominent in the initial years following diagnosis.
Cause of death unrelated to epilepsy
Clearly, people with epilepsy are subject to the same intercurrent illnesses as the rest of the population. However, some studies have shown that the risk of dying from ischaemic heart disease may be increased in epilepsy 38 , while others have not shown this [39] [40] [41] .
Cause of death related to underlying disease
As seen in the table, the SMR is greatly increased for CNS tumours. Other underlying diseases which increase the mortality rate include cerebrovascular disease 39 , cerebral infective agents and inherited disorders.
Cause of death related to epilepsy
Epilepsy related deaths can be divided among seizure related deaths (e.g. status epilepticus, accidents including drowning), treatment related deaths, and Sudden Unexpected Death in Epilepsy. Status epilepticus affects approximately 50 patients per 100 000 population annually, and is associated with significant mortality rates of 15 to 20% in adults and 3 to 15% in children 42 . Death due to accidents, most commonly drowning 43 , is unfortunately not rare. Drowning most commonly occurs whilst swimming or in the bath. Supervision is essential, but swimming should not be discouraged. A recent report suggested that those with a history of tonic seizures are at particular risk 44 . Other accidental causes of death include head trauma and burns 43 .
Treatment related deaths
Treatment related deaths in epilepsy can be drug related, or related to surgical procedures, but these are rare events.
Drug related deaths are either dose related, and therefore usually occur when taken in overdosage, or idiosyncratic. Phenobarbitone overdosage can cause respiratory depression and coma, as can massive overdose with valproate. Overdosage with phenytoin may cause respiratory and circulatory depression.
Phenytoin hypersensitivity can lead to haemopoietic and immune complications, which may be fatal, and ethosuximide can also cause haematological disorders. Valproate can cause hepatic failure and pancreatitis and lamotrigine may cause 'Steven's Johnson syndrome', toxic epidermal necrolysis or disseminated intravascular coagulation. Felbamate is associated with idiosyncratic aplastic anaemia and with liver failure. Idiosyncratic drug reactions are unusual.
Most studies of epilepsy surgery report that one to five percent of patients have moderate to severe adverse sequelae, including, occasionally, death 45 . Vagal nerve stimulation does not appear to carry a large risk of excess death.
Suicide
The suicide rate has been found to be increased in some studies of epilepsy 38, 46 , but not in others 40, 47 . Early studies showed the suicide rate was particularly increased in those with temporal lobe epilepsy, and in the early years of the condition 46 .
SUDEP
Sudden Unexpected Death in Epilepsy (SUDEP) is a rare cause of death overall, but is more common in those with chronic epilepsy. The rate of sudden unexpected death is over 20 times higher in those with epilepsy than in the general population 48 . It occurs in both symptomatic epilepsies and primary generalized epilepsy, is rare in remission 49 , and is often though to be a seizure-related event. It has been suggested that SUDEP is associated with subtherapeutic post-mortem serum AED levels 50 , suggesting non-compliance. However, a study comparing levels in subjects dying from SUDEP with those in patients who had epilepsy but died from other causes, found no difference in serum AED levels 51 . Recent work suggests that both central and obstructive apnoea may be important in the genesis of SUDEP 52 .
Other causes of death
Whilst death in epilepsy can be attributed directly or indirectly to the cause or effects of epilepsy in some cases, other causes for elevated SMRs remain unclear. It is likely that death due to cancer is more frequent in people with epilepsy than in the general population. It is postulated that the increase in death due to pneumonia might be secondary to aspiration during seizures; this hypothesis has not yet been tested.
CONCLUSION
• Epilepsy is a common condition and affects 1 in 200 people of the UK population at any one time.
• The highest incidence is at the two extremes of life, with 50% of cases being under age one or over 60.
• Recent advances in MRI neuroimaging have increased the percentage of people in whom a putative aetiology can be found.
• The majority of people with epilepsy have good seizure control with AEDs.
• The risk of seizure recurrence is greater in the first weeks or months after an initial seizure.
• The prognosis is largely determined by the background aetiology.
• A large number of seizures at an early stage may indicate a guarded prognosis.
• The mortality rate is slightly but significantly increased in those with epilepsy.
• In newly diagnosed epilepsy death is usually attributed to the underlying aetiology.
• In chronic epilepsy, a significant cause of death is SUDEP.
